www.HepCChallenge.org
August
2010
Clinical
Trials, Cohort Studies, Pilot Studies
A sustained virologic response is
durable in patients with chronic hepatitis C treated with peginterferon alfa-2a
and ribavirin. Swain MG, Lai MY, Shiffman ML, et al.
Gastroenterology. 2010 Jul 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20637202
Retreatment of hepatitis C
patients with pegylated interferon combined with ribavirin in non-responders to
interferon plus ribavirin. Is it different in real life? Goncales
FL Jr, Moma CA, Vigani AG, et al. BMC Infect Dis. 2010 Jul 20;10(1):212. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20646277
Components of metabolic syndrome
are independent predictors of mortality in patients with chronic liver disease:
a population-based study. Stepanova M, Rafiq N, Younossi ZM.
Inova
Health System Falls Church, Virginia, USA. Gut. 2010 Jul 26. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20660697
Interferon reduces the risk of
hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver
cirrhosis. Masuzaki R, Yoshida H, Omata M. Oncology. 2010
Jul;78 Suppl 1:17-23. Epub 2010 Jul 8.
http://www.ncbi.nlm.nih.gov/pubmed/20616579
An updated follow-up of chronic
hepatitis C after three decades of observation in pediatric patients cured of
malignancy. Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido
M, Carli M. Pediatr Blood Cancer. 2010 Jul 15;55(1):108-12.
http://www.ncbi.nlm.nih.gov/pubmed/20127849
Peginterferon alpha-2a and
ribavirin treatment of patients with haemophilia and hepatitis C virus
infection: a single-centre study of 367 cases. Alavian
SM, Tabatabaei SV, Keshvari M, et al. Liver Int. 2010 Jul 8. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20629950
Hyperinsulinaemia reduces the
24-h virological response to PEG-interferon therapy in patients with chronic
hepatitis C and insulin resistance. Bortoletto G, Scribano L, Realdon S, et al. J Viral
Hepat. 2010 Jul;17(7):475-80.
http://www.ncbi.nlm.nih.gov/pubmed/19878535
Influence of alpha-1 antitrypsin
heterozygosity on treatment efficacy of HCV combination therapy. Kok KF,
van Soest H, van Herwaarden AE, et al. Eur J Gastroenterol Hepatol. 2010
Jul;22(7):808-12.
http://www.ncbi.nlm.nih.gov/pubmed/19794310
Is irritable bowel syndrome
associated with chronic hepatitis C? Fouad YM, Makhlouf MM, Khalaf H, et al. J
Gastroenterol Hepatol. 2010 Jul;25(7):1285-8.
http://www.ncbi.nlm.nih.gov/pubmed/20594257
Reinfection with hepatitis C
virus following sustained virological response in injection drug users. Grebely
J, Knight E, Ngai T, et al. J Gastroenterol Hepatol. 2010 Jul;25(7):1281-4.
http://www.ncbi.nlm.nih.gov/pubmed/20594256
High prevalence of late relapse
and reinfection in prisoners treated for chronic hepatitis C.
Bate
JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. J Gastroenterol Hepatol. 2010
Jul;25(7):1276-80.
http://www.ncbi.nlm.nih.gov/pubmed/20594255
Randomized trial of albinterferon
alfa-2b for the treatment of patients with chronic hepatitis C Virus Genotype 2
or 3. Nelson DR, Benhamou Y, Chuang WL, et al. Gastroenterology. 2010 Jul 2.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20600017
Randomized trial of albinterferon
alfa-2b for the treatment of patients with chronic hepatitis c virus genotype
1. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Gastroenterology. 2010 Jul 2.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20600013
Meta-analysis
shows extended therapy improves response of patients with chronic hepatitis C
virus genotype 1 infection. Farnik
H, Lange CM, Sarrazin C, et al. Clin Gastroenterol Hepatol. 2010 Jul 2. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20601130
Basic
and Applied Science, Pre-Clinical Studies
Impairment of TLR7-dependent
signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders
to interferon/ribavirin therapy. Simone O, Tortorella C,
http://www.ncbi.nlm.nih.gov/pubmed/20390327
Safety
and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to
healthy adults. Frey
SE, Houghton M, Coates S, et al. Vaccine. 2010 Jul 6. [Epub ahead of print]
Abrignani S, Chien D, Rosa D, et al. Vaccine. 2010 Jul 6. [Epub ahead of print]
Ratio
of HCV structural antigens in protein-based vaccine formulations is critical
for functional immune response induction. Martínez-Donato G, Musacchio A, Alvarez-Lajonchere
L, et al. Biotechnol Appl Biochem. 2010 Jul 9;56(3):111-8.
http://www.ncbi.nlm.nih.gov/pubmed/20515441
A
polymorphism near IL28B is associated with spontaneous clearance, of acute
hepatitis C virus and jaundice. Tillmann
HL, Thompson AJ, Patel K, et al. Gastroenterology. 2010 Jul 13. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20637200
ITPA
polymorphism affects ribavirin-induced anemia and outcome of therapy - a
Genome-wide study of Japanese HCV patients. Ochi H, Maekawa T, Abe H, et al. Gastroenterology.
2010 Jul 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20637204
Adaptation
of hepatitis C virus to mouse CD81 permits infection of mouse cells in the
absence of human entry factors. Bitzegeio
J, Bankwitz D, Hueging K, et al. PLoS Pathog. 2010 Jul 1;6:e1000978.
http://www.ncbi.nlm.nih.gov/pubmed/20617177
Heat
shock protein 72 is associated with the hepatitis C virus replicase complex and
enhances viral RNA replication. Chen
YJ, Chen YH, Chow LP, et al. J Biol Chem. 2010 Jul 2. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20601427
HIV/HCV/HBV
Coinfection
Hepatitis C virus infection is
associated with endothelial dysfunction in HIV/hepatitis C virus coinfected
patients. Castro IF, Micheloud D, Berenguer J, et al. AIDS.
2010 Jul 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20616694
Treatment of hepatitis C in HCV
mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison
study. Gonvers JJ, Heim MH, Cavassini M, et al. Swiss Med Wkly.
2010 Jul 19;140:w13055. doi: 10.4414/smw.2010.13055.
http://www.ncbi.nlm.nih.gov/pubmed/20648398
HBsAg profiles in patients
receiving peginterferon alfa-2a plus ribavirin for the treatment of dual
chronic infection with hepatitis B and C viruses. Yu ML,
Lee CM, Chuang WL, et al. J Infect Dis. 2010 Jul 1;202(1):86-92.
http://www.ncbi.nlm.nih.gov/pubmed/20482252
Management of HIV and hepatitis
virus coinfection. Mendes-Corrêa M, Núñez M. Expert Opin Pharmacother.
2010 Jul 14. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20629586
Hepatic steatosis in patients coinfected
with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the
risk factors. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatology.
2010 Jul;52(1):71-8.
http://www.ncbi.nlm.nih.gov/pubmed/20578130
Interobserver concordance in the
assessment of liver fibrosis in HIV/HCV-coinfected patients using transient
elastometry. Neukam K, Recio E, Camacho A, et al. Eur J
Gastroenterol Hepatol. 2010 Jul;22(7):801-7.
http://www.ncbi.nlm.nih.gov/pubmed/19773664
Effect of control selection on
sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV
co-infected patients. Nilsson J, Weiland O. Scand J Infect Dis. 2010
Jul;42(6-7):533-9.
http://www.ncbi.nlm.nih.gov/pubmed/20214543
Prevalence and correlates of
co-infection with human immunodeficiency virus and hepatitis C virus in male
injection drug users in Iran. Hosseini M, SeyedAlinaghi S, Kheirandish P, et al.
Arch Iran Med. 2010 Jul;13(4):318-23.
http://www.ncbi.nlm.nih.gov/pubmed/20597566
Prevalence of hepatitis C virus
and hepatitis B virus infections in HIV-positive Chinese patients. Yan YX,
Gao YQ, Sun X, et al. Epidemiol Infect. 2010 Jul 2:1-7. [Epub ahead of print]
Wang W,
Huang XJ, Zhang T, Li M, Zang CP, Li ZC, Wu H.
http://www.ncbi.nlm.nih.gov/pubmed/20598209
Impact of hepatitis C viral
replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and
after antiretroviral therapy. Potter M, Odueyungbo A, Yang H, et al. AIDS. 2010
Jul 31;24(12):1857-65.
http://www.ncbi.nlm.nih.gov/pubmed/20479633
Hepatitis C infection in HIV-1
natural viral suppressors. Sajadi MM, Shakeri N, Talwani R, Redfield RR. AIDS.
2010 Jul 17;24(11):1689-95.
http://www.ncbi.nlm.nih.gov/pubmed/20467290
IP-10 predicts the first phase
decline of HCV RNA and overall viral response to therapy in patients
co-infected with chronic hepatitis C virus infection and HIV. Falconer
K, Askarieh G, Weis N, et al. Scand J Infect Dis. 2010 Jul 7. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20608766
Acute hepatitis C in HIV-infected
men who have sex with men: an emerging sexually transmitted infection. van de
Laar TJ, Matthews GV, Prins M, Danta M. AIDS. 2010 Jul 31;24(12):1799-812.
http://www.ncbi.nlm.nih.gov/pubmed/20601854
Cellular immune responses to HCV
core increase and HCV RNA levels decrease during successful antiretroviral
therapy. Rohrbach J, Robinson N, Harcourt G, et al. Gut. 2010
Jul 26. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20660698
Changes in liver stiffness in
patients with chronic hepatitis C with and without HIV co-infection treated
with pegylated interferon plus ribavirin. Macías J, Del Valle J,
Rivero A, et al. J Antimicrob Chemother. 2010 Jul 22. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20656678
Hepatitis
C transmission, prevention, and treatment knowledge among patients with HIV.
Proeschold-Bell RJ, Blouin R, Reif
S, et al. South Med J. 2010 Jul;103(7):635-41.
http://www.ncbi.nlm.nih.gov/pubmed/20531062
Complementary and
Alternative Medicine
Vitamin D supplementation
improves response to antiviral treatment for recurrent hepatitis C. Bitetto
D, Fabris C, Fornasiere E, Transpl Int. 2010 Jul 22. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20649944
Diagnostics,
Epidemiology, and Miscellaneous Works
Determining rates of hepatitis C
in a clozapine treated cohort. Sockalingam S, Shammi C, Powell V, Barker L,
Remington G. Schizophr Res. 2010 Jul 5. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20605572
Liver fibrosis in chronic
hepatitis C virus infection: differentiating minimal from intermediate fibrosis
with perfusion CT. Ronot M, Asselah T, Paradis V, et al. Radiology.
2010 Jul;256(1):135-42.
http://www.ncbi.nlm.nih.gov/pubmed/20574090
Direct detection of unamplified
hepatitis C virus RNA using unmodified gold nano-particles. Shawky
SM, Bald D, Azzazy HM. Clin Biochem. 2010 Jul 19. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20627095
Early viral and peripheral blood
mononuclear cell responses to pegylated interferon and ribavirin treatment: the
first 24 h. Devitt E, Lawless MW, Sadlier D, et al. Eur J
Gastroenterol Hepatol. 2010 Jul 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20631625
Hepatic fibrosis in patients with
chronic hepatitis C assessed by transient elastography: implications for
determining the efficacy of antiviral therapy. Mendoza
J, Trapero-Marugán M, González-Moreno L, et al. Rev Esp Enferm Dig. 2010
Jul;102(7):426-34.
http://www.ncbi.nlm.nih.gov/pubmed/20617863
MELD Era: Is this time to replace
the original Child-Pugh score in patients with de-compensated cirrhosis of
liver. Shaikh S, Ghani H, Memon S, Baloch GH, Jaffery M,
Shaikh K. J Coll Physicians Surg Pak. 2010 Jul;20(7):432-5.
http://www.ncbi.nlm.nih.gov/pubmed/20642940
Hepatitis
C virus prevalence and clearance among US Blood Donors, 2006-2007: associations
with birth cohort, multiple pregnancies, and body mass index. Murphy EL, Fang J, Tu Y, et al. J
Infect Dis. 2010 Jul 9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20617929
Alcohol
and hepatitis C virus-interactions in immune dysfunctions and liver damage.
Szabo G, Wands JR, Eken A, et al.
Alcohol Clin Exp Res. 2010 Jul 1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20608905
Emerging
therapies for hepatitis C virus. Birerdinc
A, Younossi ZM. Expert Opin Emerg Drugs. 2010 Jul 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20629602
Direct
economic burden of chronic hepatitis C virus in a United States managed care
population. Davis
KL, Mitra D, Medjedovic J, Beam C, Rustgi V. J Clin Gastroenterol. 2010 Jul 10.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20628308
Viral
pathogens. Ragni
MV, Sherman KE, Jordan JA. Haemophilia. 2010 Jul;16 Suppl 5:40-6.
http://www.ncbi.nlm.nih.gov/pubmed/20590855
Pharmacy
participation in non-prescription syringe sales in Los Angeles and San
Francisco Counties, 2007. Cooper
EN, Dodson C, Stopka TJ, Riley ED, Garfein RS, Bluthenthal RN. J Urban Health.
2010 Jul;87(4):543-52.
http://www.ncbi.nlm.nih.gov/pubmed/20549568
Population
risk of syringe reuse: estimating the probability of transmitting bloodborne
disease. Sikora
C, Chandran AU, Joffe AM, Johnson D, Johnson M. Infect Control Hosp Epidemiol.
2010 Jul;31(7):748-54.
http://www.ncbi.nlm.nih.gov/pubmed/20509761
Use
of gloves and reduction of risk of injury caused by needles or sharp medical
devices in healthcare workers: Results from a case-crossover study. Kinlin LM, Mittleman MA, Harris
AD, Rubin MA, Fisman DN. Infect Control Hosp Epidemiol. 2010 Jul 26. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20658920
Sex and age differences in lipid
response to chronic infection with the hepatitis C virus in the United States
National Health and Nutrition Examination Surveys.
Lao XQ,
Thompson A, McHutchison JG, McCarthy JJ. J Viral Hepat. 2010 Jul 19. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20642483
Development of the hepatitis C
self-management program. Groessl EJ, Weingart KR, Gifford AL, Asch SM, Ho SB.
Patient Educ Couns. 2010 Jul 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20638216
Implications of hepatitis C virus
infection for behavioral symptoms and activities of daily living. Posada
C, Moore DJ, Woods SP, et al. J Clin Exp Neuropsychol. 2010 Jul;32(6):637-44.